Waist Circumference Independently Associated with Breast Cancer Risk
the Cancer Therapy Advisor take:
Overall adiposity was positively associated with overall breast cancer risk — specifically waist circumference with overall risk in premenopausal and postmenopausal women, according to an article published online in the journal Cancer.
Participants enrolled in the study from 2003 to 2009 included a total of 50,884 women in a Sister Study cohort (aged 35 to 74 years).
In order to be eligible to participate, the women must have had a sister previously diagnosed with breast cancer.
Results showed 2,009 breast cancer diagnoses were made during the follow-up period (mean=5.4 years). Overall breast cancer risk had positive associations with weight, body mass index (BMI), waist circumference, and waist-to-hip ratio.
Hazard ratios (HR) for these associations were greater among postmenopausal women, women with hormonally responsive tumors, and those not currently using postmenopausal hormones.
Furthermore, waist circumference correlations continued to be present after adjusting for BMI in both postmenopausal women (81-88 cm vs. ≤80 cm: HR = 1.16; 95% CI: 1.01, 1.35 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 1.10, 1.54) and premenopausal women (81-88 cm vs. ≤80 cm: HR = 1.56; 95% CI: 1.19, 2.04 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 0.91, 1.87).
Overall adiposity was positively associated with overall breast cancer risk in premenopausal and postmenopausal women.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC